Jupiter Asset Management Ltd. Sells 323,931 Shares of Intellia Therapeutics, Inc. $NTLA

Jupiter Asset Management Ltd. lessened its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 23.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,037,918 shares of the company’s stock after selling 323,931 shares during the quarter. Jupiter Asset Management Ltd. owned about 0.90% of Intellia Therapeutics worth $9,331,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Intellia Therapeutics in the third quarter worth approximately $30,000. Advisory Services Network LLC purchased a new position in Intellia Therapeutics in the 3rd quarter worth approximately $33,000. Headlands Technologies LLC bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth $26,000. Comerica Bank increased its holdings in shares of Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NTLA stock opened at $14.07 on Friday. The firm has a market cap of $1.97 billion, a P/E ratio of -3.97 and a beta of 1.93. The firm’s fifty day moving average is $13.55 and its 200 day moving average is $12.00. Intellia Therapeutics, Inc. has a 52 week low of $6.83 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same period in the previous year, the firm posted ($1.10) earnings per share. As a group, analysts forecast that Intellia Therapeutics, Inc. will post -3.29 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NTLA. Morgan Stanley lifted their price objective on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th. Canaccord Genuity Group lowered their price target on Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Sanford C. Bernstein upped their price objective on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Finally, Chardan Capital increased their price objective on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.25.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.